Charles Schwab Investment Management Inc Pacira Bio Sciences, Inc. Transaction History
Charles Schwab Investment Management Inc
- $527 Billion
- Q4 2024
A detailed history of Charles Schwab Investment Management Inc transactions in Pacira Bio Sciences, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 502,204 shares of PCRX stock, worth $11.5 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
502,204
Previous 431,897
16.28%
Holding current value
$11.5 Million
Previous $6.5 Million
45.46%
% of portfolio
0.0%
Previous 0.0%
Shares
30 transactions
Others Institutions Holding PCRX
# of Institutions
260Shares Held
49.8MCall Options Held
1.03MPut Options Held
139K-
Black Rock Inc. New York, NY8.01MShares$183 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.26MShares$120 Million0.0% of portfolio
-
Pacer Advisors, Inc. Malvern, PA3.26MShares$74.6 Million0.15% of portfolio
-
D. E. Shaw & Co., Inc. New York, NY2.26MShares$51.6 Million0.03% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny1.99MShares$45.6 Million0.06% of portfolio
About Pacira BioSciences, Inc.
- Ticker PCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 45,824,200
- Market Cap $1.05B
- Description
- Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid ...